# US 2024/0003918 A1 · Non-invasive assessment of alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0003918 A1
- Document ID: US20240003918A1
- Status: Published application
- Kind: A1
- Application number: 18/254,438
- Filed: 2021-11-29
- Published: 2024-01-04
- Earliest claimed: 2020-11-30
- Assignees: Enigma Biointelligence, Inc.
- Applicants: Enigma Biointelligence, Inc.
- Inventors: Michael Reitermann; Thomas H. Tulip; Mathotaarachchilage Sulantha Sanjeewa Mathotaarachchi
- Web page: https://patentgrep.com/patent/US20240003918A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present disclosure generally to non-invasive methods and tests that measure biomarkers and collect clinical parameters from subjects, and computer-implemented processes for assessing a likelihood that a patient has or will develop Alzheimer's Disease, e.g., by assigning the subject an Alzheimer's Disease risk score.

## Claims

### Claim 1

A method for scoring a subject's risk for developing or already having Alzheimer's disease (AD), comprising:
(a) receiving a dataset associated with the subject, wherein said dataset comprises quantitative data for at least 4 protein markers in one or more fluid samples from the subject, optionally wherein:
(i) the fluid samples are selected from blood and cerebral spinal fluid (CSF); and/or
(ii) the protein markers comprise at least 3 of a tau peptide marker, an amyloid peptide marker, a neurodegeneration marker, a metabolic disorder marker, and an inflammation marker;
(b) generating an AD risk score from said dataset, thereby scoring the subject's risk for developing or already having AD.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dataset is obtained by a method comprising:
(a) obtaining said one or more fluid samples from the subject;
(b) performing an antibody or antigen assay on the one or more fluid samples to measure the levels of the at least 4 protein markers; and
(c) quantitating the at least 4 protein markers.

### Claim 3

A method of analyzing a sample from a subject comprising the steps of:
(a) obtaining one or more fluid samples from a subject, optionally wherein the fluid samples are selected from blood and cerebral spinal fluid (CSF);
(b) performing an antibody or antigen assay on the one or more fluid samples to measure the levels of at least 4 protein markers, optionally wherein the protein markers comprise at least 3 of a tau peptide marker, an amyloid peptide marker, a neurodegeneration marker, a metabolic disorder marker, and an inflammation marker;
(c) generating quantitative values of the at least 4 protein markers;
(d) storing the quantitative values in a dataset associated with the subject; and
(e) generating an AD risk score from the dataset, thereby analyzing the sample from the subject.

### Claim 4 (depends on 3)

The method of claim 3, which further comprises
(a) repeating steps (a) through (d) after at least 1 year;
(b) storing the quantitative values generated in step (g) in a subsequent dataset associated with the subject; and
(c) generating a subsequent AD risk score from the subsequent dataset.

### Claim 5 (depends on 4)

A method of identifying a subject in need of AD testing, comprising:
(a) performing the method of claim 4 on fluid samples from a subject;
(b) determining if there is a change between the AD risk score and the subsequent AD risk score indicative of an increased risk for AD; and
(c) conducting further testing of the subject for indicators of AD.

### Claim 6 (depends on 5)

The method of claim 5, wherein the further testing comprises PET amyloid and/or tau scans, amyloid scanning methods, lumbar puncture amyloid and/or tau procedures, structural MRI, neuropsychological testing or a combination thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 to 6, wherein the step of generating an AD risk score method is computer implemented.

### Claim 8

A computer implemented method for assessing a subject's risk for developing or already having AD, the method comprising executing, in a computer system having one or more processors coupled to a memory storing one or more computer readable instructions for execution by the one or more processors, the one or more computer readable instructions comprising instructions for:
(a) storing a dataset associated with the subject, wherein said dataset comprises quantitative data for at least 4 protein markers in one or more fluid samples from the subject, wherein:
(i) the fluid samples are selected from blood and cerebral spinal fluid (CSF); and/or
(ii) the protein markers comprise at least 3 of a tau peptide marker, an amyloid peptide marker, a neurodegeneration marker, a metabolic disorder marker, and an inflammation marker; and
(b) generating an AD risk score for the subject from the dataset, thereby scoring the subject's risk for developing or already having AD.

### Claim 9 (depends on 7, 8)

The method of claim 7 or claim 8, wherein the AD risk score is generated using a statistics- and/or artificial intelligence-based algorithm.

### Claim 10 (depends on 9)

The method of claim 9, wherein the AD risk score is a generated using an artificial intelligence-based algorithm, optionally wherein the artificial intelligence-based algorithm is a logistic regression-based algorithm, a light GBM-based algorithm, a Random Forest-based algorithm, a CatBoost-based algorithm, a linear discriminant analysis-based algorithm, an Adaptive Boosting-based algorithm, an Extreme Gradient Boosting-based algorithm, an Extra Trees-based algorithm, a Naïve-Bayes-based algorithm, a K-Nearest neighbor-based algorithm, a Gradient Boosting-based algorithm, or a Support Vector-based algorithm.

### Claim 11 (depends on 10)

The method of claim 10, wherein the AD risk score predicts (i) the subject's brain amyloid load, (ii) the subject's brain tau load, (iii) brain neurodegeneration in the subject, or (iv) whether the subject exhibits symptoms sufficient for a diagnosis of mild cognitive impairment or AD.

### Claim 12 (depends on 10, 11)

The method of claim 10 or claim 11, which comprises generating two or more, three or more, four or more, five or more, or six or more AD risk scores from the dataset that individually predict (i) the subject's brain amyloid load, (ii) the subject's brain tau load, (iii) brain neurodegeneration in the subject, or (iv) whether the subject exhibits symptoms sufficient for a diagnosis of mild cognitive impairment or AD.

### Claim 13 (depends on 11, 12)

The method of claim 11 or claim 12, which comprises generating an AD risk score from the dataset that predicts the subject's brain amyloid load.

### Claim 14 (depends on 13)

The method of claim 13, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have an amyloid PET centiloid value above or below a cutoff value, optionally wherein the AD risk score is a generated using a Random Forest-based algorithm or CatBoost-based algorithm.

### Claim 15 (depends on 13, 14)

The method of claim 13 or claim 14, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have an amyloid PET centiloid value of less than 12, optionally wherein the AD risk score is a generated using a Random Forest-based algorithm.

### Claim 16 (depends on 13, 14, 15)

The method of any one of claims 13 to 15, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have an amyloid PET centiloid value of greater than or equal to 21, optionally wherein the AD risk score is a generated using a CatBoost-based algorithm.

### Claim 17 (depends on 13, 14, 15, 16)

The method of any one of claims 13 to 16, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have a full brain amyloid standardized uptake value ratio (SUVR) above a cutoff value.

### Claim 18 (depends on 13, 14, 15, 16, 17)

The method of any one of claims 13 to 17, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have a volume of interest (VOI)-based amyloid standardized uptake value ratio (SUVR) or centiloid value above a cutoff value.

### Claim 19 (depends on 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 11 to 18, which comprises generating an AD risk score from the dataset that predicts the subject's brain tau load.

### Claim 20 (depends on 19)

The method of claim 19, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have a tau load which is greater than a cutoff value, optionally wherein the cutoff value is based on a standardized measure of brain tau load.

### Claim 21 (depends on 19, 20)

The method of claim 19 or claim 20, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have a Tau PET standardized uptake value ratio (SUVR) in the subject's mesial temporal region which is greater than a cutoff value, optionally wherein the AD risk score is a generated using a CatBoost-based algorithm.

### Claim 22 (depends on 19, 20, 21)

The method of any one of claims 19 to 21, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have a Tau PET standardized uptake value ratio (SUVR) in the subject's mesial temporal region which is greater than the 95th percentile SUVR in healthy subjects, optionally wherein the AD risk score is a generated using a CatBoost-based algorithm.

### Claim 23 (depends on 19, 20, 21, 22)

The method of any one of claims 19 to 22, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have a Tau PET standardized uptake value ratio (SUVR) in the subject's temporal region which is greater than a cutoff value, optionally wherein the AD risk score is a generated using a CatBoost-based algorithm.

### Claim 24 (depends on 19, 20, 21, 22, 23)

The method of any one of claims 19 to 23, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have a Tau PET standardized uptake value ratio (SUVR) in the subject's temporal region which is greater than the 95th percentile SUVR in healthy subjects, optionally wherein the AD risk score is a generated using a CatBoost-based algorithm.

### Claim 25 (depends on 21, 22, 23, 24)

The method of any one of claims 21 to 24, wherein the Tau PET standardized uptake value ratio (SUVR) is a MK6240, Flortaucipir, RO948, Genentech Tau Probe (GTP) 1, or PI-2620 Tau PET standardized uptake value ratio (SUVR).

### Claim 26 (depends on 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 19 to 25, which comprises generating an AD risk score from the dataset that predicts the subject's full brain tau load.

### Claim 27 (depends on 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 19 to 26, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have a volume of interest (VOI)-based tau standardized uptake value ratio (SUVR) above a cutoff value.

### Claim 28 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 11 to 27, which comprises generating an AD risk score from the dataset that predicts brain neurodegeneration in the subject.

### Claim 29 (depends on 28)

The method of claim 28, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have a clinical dementia rating indicative of brain neurodegeneration, optionally wherein the AD risk score is a generated using a Light GBM-based algorithm.

### Claim 30 (depends on 29)

The method of claim 29, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have a clinical dementia rating greater than or equal to 0.5, optionally wherein the AD risk score is a generated using a Light GBM-based algorithm.

### Claim 31 (depends on 28, 29, 30)

The method of any one of claims 28 to 30, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have a cognitive assessment test score indicative of brain neurodegeneration, optionally wherein the cognitive assessment is the mini-mental state examination (MMSE), Montreal Cognitive Assessment (MOCA), Alzheimer's Disease Assessment Scale-Cognitive section (ADAS-Cog), Delis-Kaplan Executive Function System (D-KEFS) test, or Addenbrookes Cognitive Assessment (ACE-R).

### Claim 32 (depends on 28, 29, 30, 31)

The method of any one of claims 28 to 31, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have a physical measure of brain neurodegeneration, optionally wherein the physical measure is a reduced cortical thickness, loss of functional connectivity or white matter hyperintensities indicative of brain neurodegeneration.

### Claim 33 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 11 to 32, which comprises generating an AD risk score from the dataset that predicts whether the subject is likely to have symptoms sufficient for a diagnosis of mild cognitive impairment or AD, optionally wherein the AD risk score is a generated using a CatBoost-based algorithm.

### Claim 34 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 11 to 33, which comprises generating (i) an AD risk score that predicts whether the subject is likely to have an amyloid PET centiloid value of less than a cutoff value, which is optionally 12; (ii) an AD risk score that predicts whether the subject is likely to have an amyloid PET centiloid value greater than or equal to a second cutoff value, which is optionally 21; (iii) an AD risk score that predicts whether the subject is likely to have a Tau PET standardized uptake value ratio (SUVR) in the subject's mesial temporal region which is greater than the 95th percentile SUVR in healthy subjects; (iv) an AD risk score that predicts whether the subject is likely to have a Tau PET standardized uptake value ratio (SUVR) in the subject's temporal region which is greater than the 95th percentile SUVR in healthy subjects; (v) an AD risk score that predicts whether the subject is likely to have a clinical dementia rating greater than or equal to 0.5; and (vi) an AD risk score that predicts whether the subject is likely to have symptoms sufficient for a diagnosis of mild cognitive impairment or AD.

### Claim 35 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 7 to 34, which further comprises classifying the subject, based on the subject's AD risk score(s), into one of at least a first risk category and a second risk category, and optionally a third risk category.

### Claim 36 (depends on 35)

The method of claim 35, wherein the first risk category indicates that the subject is at a low risk of developing AD.

### Claim 37 (depends on 36)

The method of claim 36, which further comprises re-testing the subject for AD in approximately 1-5 years if the subject's AD risk score(s) indicate that the subject is at low risk of developing AD.

### Claim 38 (depends on 37)

The method of claim 37, which further comprises re-testing the subject for AD in approximately 3-5 years if the subject's AD risk score(s) indicate that the subject is at low risk of developing AD.

### Claim 39 (depends on 35, 36, 37, 38)

The method of any one of claims 35 to 38, wherein the second risk category indicates that the subject has AD or is at elevated risk of developing AD.

### Claim 40 (depends on 39)

The method of claim 39, wherein the second risk category indicates that the subject has AD or is at high risk of developing AD.

### Claim 41 (depends on 40)

The method of claim 40, which further comprises conducting further testing of the subject for indicators of AD if the subject has an AD risk score(s) indicating that the subject has AD or is at high risk of developing AD, optionally wherein the further testing comprises PET amyloid and/or tau scans, amyloid scanning methods, lumbar puncture amyloid and/or tau procedures, structural MRI, functional MRI, neuroinflammation scanning, diffuse tensor imaging, neuropsychological testing and/or a combination thereof.

### Claim 42 (depends on 40, 41)

The method of claim 40 or claim 41, which further comprises generating, in a computerized system, a report recommending administering one or more AD therapeutics to the subject if the subject has an AD risk score(s) indicating that the subject has AD or is at high risk of developing AD.

### Claim 43 (depends on 41, 42)

The method of claim 41 or claim 42, which further comprises administering one or more AD therapeutics to the subject if the subject has an AD risk score(s) indicating that the subject has AD or is at high risk of developing AD.

### Claim 44 (depends on 42, 43)

The method of claim 42 or claim 43, wherein the one or more AD therapeutics comprise an amyloid disease modifying therapy, a tau therapy, a cholinesterase inhibitor, an NMDA receptor blocker, or a combination thereof.

### Claim 45 (depends on 44)

The method of claim 44, wherein the one or more AD therapeutics comprise aducanumab-avwa.

### Claim 46 (depends on 41, 42, 43, 44, 45)

The method of any one of claims 41 to 45, which comprises further enrolling the subject in a clinical trial for a candidate AD therapeutic if the subject has an AD risk score(s) indicating that the subject has AD or is at high risk of developing AD.

### Claim 47 (depends on 46)

The method of claim 46, which further comprises administering the candidate AD therapeutic to the subject.

### Claim 48 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 35 to 47, which comprises classifying the subject, based on the subject's AD risk score(s), into one of at least a first risk category a second risk category, and a third risk category.

### Claim 49 (depends on 48)

The method of claim 48, wherein the third risk category indicates that the subject is at moderate risk of developing AD.

### Claim 50 (depends on 49)

The method of claim 49, which further comprises re-testing the subject for AD in approximately 1-2 years if the subject's AD risk score(s) indicate that the subject is at moderate risk of developing AD.

### Claim 51 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 35 to 50, further comprising generating, in a computerized system, a report comprising a representation of the risk category into which the has been classified.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 1 to 51, wherein the dataset further comprises the subject's family history of AD.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 1 to 52, wherein the dataset further comprises the age, gender or education of the subject, or any combination thereof.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 1 to 53, wherein the data set further comprises one or more genetic risk markers of AD, optionally wherein the one or more genetic risk markers of AD comprise APO E4, Clusterin (CLU), Sortilin-related receptor-1 (SORL1), ATP-binding cassette subfamily A member 7 (ABCA7), or a combination thereof.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1 to 54, wherein the step of generating an AD risk score is computer implemented, and wherein the method further comprises providing a notification to the user recommending further testing and/or a neurologic consultation when the subject has an AD risk score(s) indicative of a high risk for developing AD.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

A method for monitoring the AD status of a subject with one or more AD risk factors, comprising:
(a) performing the method of any one of claims 1 to 55 on one or more fluid samples from the subject and assigning the subject a first AD risk score at a first time point;
(b) performing the method of any one of claims 1 to 55 on one or more fluid samples from the subject and assigning the subject a second AD risk score at a second time point;
(c) comparing the first AD risk score and the second AD risk score to determine if the subject's AD risk score has increased,
thereby monitoring the AD status of the subject.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of claim 56, which further comprises:
(a) performing the method of any one of claims 1 to 55 on one or more fluid samples from the subject and assigning the subject a third AD risk score at a third time point;
(b) comparing the third AD risk score and the first AD risk score and/or second AD risk score to determine if the subject's AD risk score has increased and/or the rate of change of the subject's AD risk score,
thereby continuing to monitor the AD status of the subject.
(c) if the subject's AD risk score has increased and/or the rate of change of the subject's AD risk score,
thereby continuing to monitor the AD status of the subject.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 1 to 57, wherein the protein markers comprise at least 5 protein markers.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 1 to 58, wherein the protein markers comprise one or more tau peptide markers, optionally wherein the one or more tau peptide markers comprise one or more phosphorylated tau peptide markers, optionally wherein the one or more tau peptide markers comprise p-tau 217, p-tau 181, p-tau 231, p-tau 235, or a combination thereof.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1 to 59, wherein the protein markers comprise one or more amyloid peptide markers, optionally wherein the one or more amyloid peptide markers comprise Aβ-40, Aβ-42, the ratio of Aβ-40:Aβ-42, the ratio of Aβ-42:Aβ-40, or a combination thereof.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The method of any one of claims 1 to 60, wherein the protein markers comprise one or more neurodegeneration markers, optionally wherein the one or more neurodegeneration markers comprise neurofilament light (“NFL”) and/or glial fibrillary acidic protein (“GFAP”).

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 1 to 61, wherein the protein markers comprise one or more metabolic disorder markers, optionally wherein the one or more metabolic disorder markers comprise HbA1c.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 1 to 62, wherein the protein markers comprise one or more inflammation markers, optionally wherein the one or more inflammation markers comprise C reactive protein (“CRP”), interleukin-6 (“IL-6”), tumor necrosis factor (“TNF”), soluble TREM 2 (“sTREM-2”), a heat shock protein, YKL-40, or a combination thereof.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 1 to 63, wherein the protein markers further comprise one or more markers other than a tau peptide marker, an amyloid peptide marker, a neurodegeneration marker, a metabolic disease marker, and an inflammation marker (“other markers”), said other markers optionally comprising a proteinopathy marker, e.g., a frontotemporal lobe dementia (FTLD) marker, a Parkinson's Disease marker, a Lewy Body dementia marker, or a combination thereof, optionally wherein the one or more other markers comprise α-synuclein and/or TDP-43.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 1 to 64, wherein the fluid samples are blood samples, optionally wherein the blood samples are plasma samples.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 1 to 64, wherein the fluid samples are samples are a combination of blood samples and CSF samples, optionally wherein the blood samples are plasma samples.

### Claim 67

A method of producing an artificial intelligence-based algorithm for generating an AD risk score for a subject, the method comprising executing, in a computer system having one or more processors coupled to a memory storing one or more computer readable instructions for execution by the one or more processors, the one or more computer readable instructions comprising instructions for:
(a) storing a dataset comprising a plurality of patient records, each patient record comprising quantitative data for at least 4 protein markers in one or more fluid samples from the patient and data for one or more AD surrogate variables for the patient, wherein:
(i) the fluid samples are selected from blood and cerebral spinal fluid (CSF); and/or
(ii) the protein markers comprise at least 3 of a tau peptide marker, an amyloid peptide marker, a neurodegeneration marker, a metabolic disorder marker, and an inflammation marker; and
(b) training a machine learning model with at least a portion of the patient records, wherein the quantitative data for the at least 4 protein markers are input variables and the data for the AD surrogate variable are output variables for the machine learning model, thereby providing an artificial intelligence-based algorithm for generating an AD risk score.

### Claim 68 (depends on 67)

The method of claim 67, wherein the artificial intelligence-based algorithm weights the at least 4 protein markers differentially.

### Claim 69 (depends on 67, 68)

The method of claim 67 or claim 68, wherein the one or more AD surrogate variables comprise brain amyloid load.

### Claim 70 (depends on 69)

The method of claim 69, wherein the patient data for brain amyloid load comprise standardized brain amyloid load data (e.g., PET centiloid data, PET SUVR data, or AmyloidIQ data).

### Claim 71 (depends on 69)

The method of claim 69, wherein the patient data for brain amyloid load comprise amyloid PET centiloid data.

### Claim 72 (depends on 69, 70, 71)

The method of any one of claims 69 to 71, wherein the at least 4 protein markers comprise one or more tau peptide markers, one or more amyloid peptide markers, one or more neurodegeneration markers, and one or more neuroinflammation markers.

### Claim 73 (depends on 72)

The method of claim 72, wherein the one or more tau peptide markers comprise one or more phosphorylated tau peptide markers (e.g., p-tau 181), the one or more amyloid peptide markers comprise Aβ-40, Aβ-42, Aβ-42:Aβ-40 ratio, Aβ-40:Aβ-42 ratio, or a combination thereof, the one or more neurodegeneration markers comprise GFAP, and the one or more neuroinflammation markers comprise sTREM-2.

### Claim 74 (depends on 72, 73)

The method of claim 72 or claim 73, wherein the artificial intelligence-based algorithm weights one or more tau peptide markers (e.g., p-tau 181) greater than one or more amyloid peptide markers (e.g., Aβ-42:Aβ-40 ratio), and wherein the artificial intelligence-based algorithm weights one or more amyloid peptide markers (e.g., Aβ-42:Aβ-40 ratio) greater than one or more neurodegeneration markers (e.g., GFAP) and one or more neuroinflammation markers (e.g., sTREM-2).

### Claim 75 (depends on 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 67 to 74, wherein the one or more AD surrogate variables comprise brain tau load.

### Claim 76 (depends on 75)

The method of claim 75, wherein the patient data for brain tau load comprise standardized brain tau load data (e.g., PET SUVR data or TauIQ data).

### Claim 77 (depends on 75)

The method of claim 75, wherein the patient data for brain tau load comprise Tau PET SUVR data.

### Claim 78 (depends on 76, 77)

The method of claim 76 or 77, wherein the Tau PET SUVR data comprise Tau PET SUVR data for the mesial temporal region of the brain.

### Claim 79 (depends on 77, 78)

The method of claim 77 or claim 78, wherein the Tau PET SUVR data comprise Tau PET SUVR data for the temporal region of the brain.

### Claim 80 (depends on 77, 78, 79)

The method of any one of claims 77 to 79, wherein the Tau SUVR data is a MK6240, Flortaucipir, RO948, Genentech Tau Probe (GTP) 1, or PI-2620 Tau PET SUVR data.

### Claim 81 (depends on 80)

The method of claim 80, wherein the Tau PET SUVR data is MK6240 Tau PET SUVR data.

### Claim 82 (depends on 75, 76, 77, 78, 79, 80, 81)

The method of any one of claims 75 to 81, wherein the at least 4 protein markers comprise one or more tau peptide markers, one or more amyloid peptide markers, one or more neurodegeneration markers and, optionally, one or more proteinopathy markers.

### Claim 83 (depends on 82)

The method of claim 82, wherein the one or more tau peptide markers comprise one or more phosphorylated tau peptide markers (e.g., p-tau 181), the one or more amyloid peptide markers comprise Aβ-40, Aβ-42, Aβ-42:Aβ-40 ratio, Aβ-40:Aβ-42 ratio, or a combination thereof, the one or more neurodegeneration markers comprise GFAP and/or NFL, and the one or more proteinopathy markers comprise TDP43.

### Claim 84 (depends on 82, 83)

The method of claim 82 or claim 83, wherein the artificial intelligence-based algorithm weights one or more of the one or more tau peptide markers (e.g., p-tau 181) greater than one or more neurodegeneration markers (e.g., GFAP), and wherein the artificial intelligence-based algorithm weights one or more neurodegeneration markers (e.g., GFAP) greater than one or more amyloid peptide markers (e.g., Aβ-42:Aβ-40 ratio).

### Claim 85 (depends on 82, 83)

The method of claim 82 or claim 83, wherein the artificial intelligence-based algorithm weights one or more tau peptide markers (e.g., p-tau 181) greater than one or more amyloid peptide markers (e.g., Aβ-42:Aβ-40 ratio), and wherein the artificial intelligence-based algorithm weights one or more amyloid peptide markers (e.g., Aβ-42:Aβ-40 ratio) greater than one or more neurodegeneration markers (e.g., GFAP).

### Claim 86 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

The method of any one of claims 67 to 85, wherein the one or more AD surrogate variables comprise brain neurodegeneration.

### Claim 87 (depends on 86)

The method of claim 86, wherein the patient data for brain neurodegeneration comprise clinical dementia rating data.

### Claim 88 (depends on 86, 87)

The method of claim 86 or claim 87, wherein the at least 4 protein markers comprise one or more tau peptide markers, one or more amyloid peptide markers, one or more neurodegeneration markers, and one or more inflammation markers.

### Claim 89 (depends on 88)

The method of claim 88, wherein the one or more tau peptide markers comprise one or more phosphorylated tau peptide markers (e.g., p-tau 181), the one or more amyloid peptide markers comprise Aβ-40, Aβ-42, Aβ-42:Aβ-40 ratio, Aβ-40:Aβ-42 ratio, or a combination thereof, the one or more neurodegeneration markers comprise GFAP, and the one or more inflammation markers comprise sTREM-2.

### Claim 90 (depends on 88, 89)

The method of claim 88 or claim 89, wherein the artificial intelligence-based algorithm weights one or more tau peptide markers (e.g., p-tau 181) greater than one or more neurodegeneration markers (e.g., GFAP), and wherein the artificial intelligence-based algorithm weights one or more neurodegeneration markers (e.g., GFAP) greater than one or more amyloid markers (e.g., Aβ-42:Aβ-40 ratio) and one or more inflammation markers (e.g., sTREM-2).

### Claim 91 (depends on 88, 89)

The method of claim 88 or claim 89, wherein the artificial intelligence-based algorithm weights one or more neurodegeneration markers (e.g., GFAP) greater than one or more inflammation markers (e.g., sTREM-2), and wherein the artificial intelligence-based algorithm weights one or more inflammation markers (e.g., sTREM-2) greater than one or more tau peptide markers (e.g., p-tau 181) one or more amyloid peptide markers (e.g., Aβ-42:Aβ-40 ratio).

### Claim 92 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91)

The method of any one of claims 67 to 91, wherein the one or more AD surrogate variables comprise clinical diagnosis of mild-cognitive impairment or AD.

### Claim 93 (depends on 92)

The method of claim 92, wherein the patient data for clinical diagnosis of mild-cognitive impairment data comprise affirmative or negative diagnosis of mild-cognitive impairment or AD.

### Claim 94 (depends on 92, 93)

The method of claim 92 or claim 93, wherein the at least 4 protein markers comprise one or more tau peptide markers, one or more amyloid peptide markers, one or more neurodegeneration markers and, optionally, one or more proteinopathy markers.

### Claim 95 (depends on 82)

The method of claim 82, wherein the one or more tau peptide markers comprise one or more phosphorylated tau peptide markers (e.g., p-tau 181), the one or more amyloid peptide markers comprise Aβ-40, Aβ-42, Aβ-42:Aβ-40 ratio, Aβ-40:Aβ-42 ratio, or a combination thereof, the one or more neurodegeneration markers comprise GFAP and/or NFL, and the one or more proteinopathy markers comprise TDP43.

### Claim 96 (depends on 94, 95)

The method of claim 94 or claim 95, wherein the artificial intelligence-based algorithm weights one or more tau peptide markers (e.g., p-tau 181) greater than one or more neurodegeneration markers (e.g., GFAP), and wherein the artificial intelligence-based algorithm weights one or more neurodegeneration markers (e.g., GFAP) greater than one or more amyloid peptide markers (e.g., Aβ-42:Aβ-40 ratio).

### Claim 97 (depends on 94, 95)

The method of claim 94 or claim 95, wherein the artificial intelligence-based algorithm weights one or more neurodegeneration markers (e.g., GFAP) greater than one or more proteinopathy markers (e.g., TDP43), and wherein the artificial intelligence-based algorithm weights one or more proteinopathy markers (e.g., TDP43) greater than one or more amyloid peptide markers (e.g., Aβ-42:Aβ-40 ratio) and greater than one or more inflammation markers (e.g., NFL).

### Claim 98 (depends on 58, 59, 60, 61, 62, 63, 64, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The method of any one of claims 67 to 97, wherein the protein markers comprise the protein markers described in any one of claims 58 to 64.

### Claim 99 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The method of any one of claims 67 to 98, wherein each patient record further comprises the age of the patient, the age of the patient at a tau PET scan, the gender of the patient, the education of the patient, data for one or more genetic risk markers of AD, or a combination thereof.

### Claim 100 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The method of any one of claims 67 to 99, wherein the fluid samples are blood samples, optionally wherein the blood samples are plasma samples.

### Claim 101 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The method of any one of claims 67 to 99, wherein the fluid samples comprise a combination blood samples and CSF samples, optionally wherein the blood samples are plasma samples.

### Claim 102 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The method of any one of claims 67 to 101, wherein the plurality of patient records comprises at least 100, at least 200, at least 300, at least 500, at least 1000, or at least 5000 patient records and/or step (b) comprises training the machine learning model with at least 100, at least 200, at least 300, at least 500, at least 500, at least 1000, or at least 5000 patient records.

### Claim 103 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102)

The method of any one of claims 67 to 102, wherein the machine learning model is a logistic regression model, a light GBM model, a Random Forest model, a CatBoost model, a linear discriminant analysis model, an Adaptive Boosting model, an Extreme Gradient Boosting model, an Extra Trees model, a Naïve-Bayes model, a K-Nearest neighbor model, a Gradient Boosting model, or a Support Vector model.

### Claim 104 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103)

A method for scoring a subject's risk for developing or already having Alzheimer's disease (AD), comprising
(a) receiving a dataset associated with the subject, wherein said dataset comprises quantitative data for at least 4 protein markers in one or more fluid samples from the subject, optionally wherein:
(i) the fluid samples are selected from blood and cerebral spinal fluid (CSF); and/or
(ii) the protein markers comprise at least 3 of a tau peptide marker, an amyloid peptide marker, a neurodegeneration marker, a metabolic disorder marker, and an inflammation marker;
(b) generating an AD risk score from said dataset using an artificial intelligence-based algorithm produced by the method of any one of claims 67 to 103, thereby scoring the subject's risk for developing or already having AD.

### Claim 105 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103)

A computer implemented method for assessing a subject's risk for developing or already having AD, the method comprising executing, in a computer system having one or more processors coupled to a memory storing one or more computer readable instructions for execution by the one or more processors, the one or more computer readable instructions comprising instructions for:
(a) storing a dataset associated with the subject, wherein said dataset comprises quantitative data for at least 4 protein markers in one or more fluid samples from the subject, wherein:
(i) the fluid samples are selected from blood and cerebral spinal fluid (CSF); and/or
(ii) the protein markers comprise at least 3 of a tau peptide marker, an amyloid peptide marker, a neurodegeneration marker, a metabolic disorder marker, and an inflammation marker; and
(b) generating an AD risk score for the subject from the dataset using the artificial intelligence-based algorithm produced by the method of any one of claims 67 to 103, thereby scoring the subject's risk for developing or already having AD.

### Claim 106 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 104, 105)

A system configured to generate an AD risk score according to any one of the methods of any one of claims 7 to 66 and 104 to 105.

### Claim 107 (depends on 106)

The system of claim 106, which comprises one or more processors coupled to a memory storing one or more computer readable instructions for execution by the one or more processors.

### Claim 108 (depends on 107)

The system of claim 107, wherein the one or more computer readable instructions comprise instructions for:
(a) storing a dataset associated with the subject, wherein said dataset comprises quantitative data for at least 4 protein markers in one or more fluid samples from the subject, wherein:
(i) the fluid samples are selected from blood and cerebral spinal fluid (CSF); and/or
(ii) the protein markers comprise at least 3 of a tau peptide marker, an amyloid peptide marker, a neurodegeneration marker, a metabolic marker, and an inflammation marker; and
(b) generating an AD risk score for the subject from the dataset.

### Claim 109 (depends on 107, 108)

The system of any one of claims 107 to 108, wherein the computer readable instructions comprise instructions for generating a report for the subject, optionally wherein the report includes the subject's AD risk score(s) and/or one or more recommendations for the subject from the subject's AD risk score(s).

### Claim 110 (depends on 107, 108, 109)

The system of any one of claims 107 to 109, wherein the computer readable instructions further comprise instructions for classifying the subject's risk of having or developing AD, optionally wherein the instructions for classifying the subject's risk of having AD comprising instructions for classifying the subject into one of at least a first risk category and a second risk category, and optionally a third risk category for having or developing.

### Claim 111 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103)

A system configured to produce an artificial intelligence-based algorithm for generating an AD risk score according to any one of claims 67 to 103.

### Claim 112 (depends on 111)

The system of claim 111, which comprises one or more processors coupled to a memory storing one or more computer readable instructions for execution by the one or more processors.

### Claim 113 (depends on 112)

The system of claim 112, wherein the one or more computer readable instructions comprise instructions for:
(a) storing a dataset comprising a plurality of patient records, each patient record comprising quantitative data for at least 4 protein markers in one or more fluid samples from the patient and data for one or more AD surrogate variables for the patient, wherein:
(i) the fluid samples are selected from blood and cerebral spinal fluid (CSF); and/or
(ii) the protein markers comprise at least 3 of a tau peptide marker, an amyloid peptide marker, a neurodegeneration marker, a metabolic disorder marker, and an inflammation marker; and
(b) training a machine learning model with at least a portion of the patient records, wherein the quantitative data for the at least 4 protein markers are input variables and the data for the AD surrogate variable are output variables for the machine learning model.

### Claim 114

A system for generating an AD risk score for a subject, comprising one or more processors coupled to a memory storing one or more computer readable instructions for execution by the one or more processors, the one or more computer readable instructions comprising instructions for:
(a) storing a dataset comprising a plurality of patient records, each patient record comprising quantitative data for at least 4 protein markers in one or more fluid samples from the patient and data for one or more AD surrogate variables for the patient, wherein:
(i) the fluid samples are selected from blood and cerebral spinal fluid (CSF); and/or
(ii) the protein markers comprise at least 3 of a tau peptide marker, an amyloid peptide marker, a neurodegeneration marker, a metabolic disorder marker, and an inflammation marker;
(b) training a machine learning model with at least a portion of the patient records, wherein the quantitative data for the at least 4 protein markers are input variables and the data for the AD surrogate variable are output variables for the machine learning model to produce an AI-based algorithm for generating an AD risk score;
(c) generating an AD risk score for the subject using the AI-based algorithm;
(d) classifying the subject as having a low risk of developing AD if the AD risk score indicates that the subject is at a low risk of developing AD, having a medium (or moderate) risk of developing AD if the AD risk score indicates that the subject is at medium (or moderate) risk of developing AD, or high risk of having or developing AD if the AD risk score indicates that the subject is at high risk of having or developing AD; and
(e) generating a report comprising a representation of the risk category into which the has been classified and/or a recommendation for the subject based on the subject's classification.

### Claim 115 (depends on 1, 105)

A tangible, non-transitory computer-readable media comprising instructions executable by a processor for executing a method according to any one of claims 1 to 105.
